Objective: The authors investigated the incidence, course, and outcome of psychotic experiences from childhood through early adulthood in the general population and examined prediction of psychotic disorder.
Methods: This was a population-based cohort study using the semistructured Psychosis-Like Symptoms Interview at ages 12, 18, and 24 (N=7,900 with any data). Incidence rates were estimated using flexible parametric modeling, and positive predictive values (PPVs), sensitivity, specificity, and area under the curve were estimated for prediction.
The participant will describe the prevalence and incidence of psychotic experiences during adolescence and early adulthood in the general population and their importance as predictors of clinical psychotic disorder.
This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.
Duration: 1 hour
Begin Date: April 1, 2020
End Date: March 31, 2022
In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™). A score of 60% or higher is required to receive credit.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Title: A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder
Authors: Sarah A. Sullivan, Ph.D., Daphne Kounali, Ph.D., Mary Cannon, Ph.D., Anthony S. David, M.D., Paul C. Fletcher, Ph.D., Peter Holmans, Ph.D., Hannah Jones, Ph.D., Peter B. Jones, Ph.D., David E.J. Linden, Ph.D., Glyn Lewis, Ph.D., Michael J. Owen, Ph.D., Michael O’Donovan, Ph.D., Alexandros Rammos, Ph.D., Andrew Thompson, M.D., Dieter Wolke, Ph.D., Jon Heron, Ph.D., Stanley Zammit, Ph.D.
Affiliations: Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, U.K. (S.A.S., D.K., H.J., J.H., S.Z.); Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin (M.C.); Institute of Mental Health, University College London (A.S.D., G.L.); Department of Psychiatry, Addenbrooke’s Hospital, University of Cambridge, Cambridge (P.C.F., P.B.J.); MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, U.K. (P.H., D.E.J.L., M.J.O., M.O.D., A.R., S.Z.); Division of Psychiatry, Warwick Medical School, Warwick, Coventry, U.K. (A.T.); Orygen, Centre of Excellence in Youth Mental Health, Melbourne, Australia (A.T.); and Department of Psychology, Division of Mental Health and Wellbeing, University of Warwick, Coventry, U.K. (D.W.).
Disclosures: Dr. Fletcher serves as a consultant for Ninja Theory Ltd., a video game design studio. Dr. Linden has received royalties from Oxford University Press and Springer Nature and editorial fees from Elsevier. Dr. Owen and Dr. O’Donovan receive support from a research grant from Takeda. The other authors report no financial relationships with commercial interests.
Discussion of unapproved or investigational use of products*: No.
*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
Ned H. Kalin, M.D. (Editor-in-Chief, AJP); Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals). Dr. Kalin has served as a consultant to the Board of Scientific Advisors, the Pritzker Neuropsychiatric Disorders Research Consortium, and the Skyland Trail Advisory Board and as Councilor, Society of Biological Psychiatry. Dr. Rodriguez has served as a consultant to Allergan, Blackthorn, Epiodyne, and Rugen. Mr. Roy and Mr. Pogachar report no financial relationships with commercial interests.
Optimal System Configuration:
- Flash Player: Adobe Flash Player 10.1+
- Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
- Operating System: Windows XP+ or Mac OS X 10.4+
- Internet Connection: 1 Mbps or higher
- Screen Resolution: 1024 x 768 pixels.
- Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
- Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit
For assistance: Contact firstname.lastname@example.org for questions about this course | Contact email@example.com for technical assistance